Anthony Robayo

Anthony Robayo

Auto-generated profile, based on publicly available information

Anthony Robayo

Department of Neurological Surgery Weill Cornell Medicine Och Spine at New York Presbyterian Hospital New York NY USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2025 in World Neurosurgery
Verified
Journal Article
Open access
CIChibuikem Anthony Ikwuegbuenyi
Chibuikem Anthony Ikwuegbuenyi
AFAlikhan B. Fidai
Alikhan B. Fidai
ACAshley Cardenas
Ashley Cardenas
NWNoah Willett
Noah Willett
ARAnthony Robayo
Anthony Robayo
RHRoger Härtl
Roger Härtl
Degenerative disc disease (DDD) is a significant cause of chronic low back pain, often leading to disability and high healthcare costs. Current treatments, including physical therapy, pain management, and surgical interventions such as spinal fusion and total disc replacement, do not reverse degeneration. Bioactive therapies offer a potential alternative by targeting the underlying degenerative process. Cell-based therapies, including the use of mesenchymal stem cells and platelet-rich plasma, aim to restore disc structure and function by promoting extracellular matrix production and reducing inflammation. Early studies show potential benefits in pain relief and disc regeneration, but long-term efficacy remains unclear. Nucleus pulposus augmentation and replacement strategies, such as the use of hydrogel implants and in situ curing polymers, are aimed at restoring disc height and biomechanical function. While these strategies are promising, issues such as implant durability and migration require further study. Total disc replacement preserves motion and avoids adjacent-segment disease, but outcomes depend on patient selection and implant design. Despite encouraging results, bioactive therapies still require research to establish long-term safety and effectiveness. Advancements in biomaterials, patient selection criteria, and clinical trials will determine their role in the future management of DDD.

2 June 2025 in World Neurosurgery
Verified
Journal Article
Open access
AFAlikhan B. Fidai
Alikhan B. Fidai
ACAshley Cardenas
Ashley Cardenas
CIChibuikem Anthony Ikwuegbuenyi
Chibuikem Anthony Ikwuegbuenyi
ARAnthony Robayo
Anthony Robayo
NWNoah Willett
Noah Willett
LBLawrence J Bonassar
Lawrence J Bonassar

31 January 2026 in Neurospine
Verified
Journal Article
Open access
RBRachel Bratescu
Rachel Bratescu
ARAnthony Robayo
Anthony Robayo
EWEvan Wang
Evan Wang
CIChibuikem Anthony Ikwuegbuenyi
Chibuikem Anthony Ikwuegbuenyi
LCLawrance K. Chung
Lawrance K. Chung
ADAo Spine Knowledge Forum Degenerative
Ao Spine Knowledge Forum Degenerative
Recurrent lumbar disc herniation (RLDH) is a common complication after discectomy, occurring in 2%–25% of patients and contributing to higher reoperation rates, reduced satisfaction, and substantial direct and indirect costs. This review evaluates the economic consequences of RLDH and the relative cost-effectiveness of available management strategies. A systematic search of OVID, MEDLINE, and the Cochrane Library was performed through August 2025. Peer-reviewed, English-language studies were included if they examined adults (≥18 years) with RLDH and reported economic data. Exclusion criteria were studies limited to primary, cervical, or thoracic herniations; animal or cadaveric models; and abstracts. Extracted variables included study design, sample size, follow-up duration, and cost components. Of 283 records identified, 220 were screened and 35 underwent full-text review. Six studies met inclusion criteria, with 2 added through citation searching. Reported costs varied considerably: repeat discectomy added $6,907 in one analysis, while fusion increased expenses by more than 350%. Across studies, repeat discectomy remained the most cost-efficient option, providing comparable outcomes with reduced perioperative expenditures. Conservative management had the lowest immediate direct costs (≈$2,300) but likely underestimates the overall burden due to unmeasured productivity losses. Annular closure devices demonstrated potential cost savings of $2,000–5,000 over 2–5 years. RLDH imposes a substantial economic burden. Heterogeneity in costing methods remains a major limitation which hinders evidence-based determinations. Greater transparency, methodological standardization, and incorporation of societal perspectives are essential to accurately assess the socioeconomic impact of RLDH.

21 April 2026 in World Neurosurgery
Verified
Journal Article
Open access
AFAlikhan B. Fidai
Alikhan B. Fidai
JBJessica Berger
Jessica Berger
ARAnthony Robayo
Anthony Robayo
AKAhmet Kartal
Ahmet Kartal
CIChibuikem Anthony Ikwuegbuenyi
Chibuikem Anthony Ikwuegbuenyi
RHRoger Härtl
Roger Härtl
Lumbar microdiscectomy improves pain and disability in patients with lumbar disc herniation, but it does not restore disc biology, and recurrent herniation at the index level remains a clinically important limitation. Intradiscal autologous bone marrow aspirate concentrate (BMAC) has growing preclinical support as a potential biologic adjunct, but human safety data remain limited. This study evaluated the safety and feasibility of intradiscal BMAC administration at the time of lumbar microdiscectomy. Patients underwent lumbar microdiscectomy and 1 mL intradiscal autologous BMAC with 1-year follow-up. Primary outcomes were injection- or procedure-related complications, readmissions, reoperations, and same-site recurrence; secondary outcomes were Oswestry Disability Index (ODI) and Numeric Rating Scale (NRS) for leg and back pain; exploratory quantitative magnetic resonance imaging (qMRI; T1-rho, T2) screened for adverse compositional changes. 27 adults underwent lumbar microdiscectomy with concurrent intradiscal BMAC injections. No intraoperative or postoperative injection- or procedure-related complications occurred. Same-site recurrence occurred in 1/27 (3.7%) and was managed without reoperation. Patient-reported outcome measures (PROMs) were completed by 18/27 (67%), and qMRI was obtained in 16, including 6 with complete imaging through 1 year. Among patients with completed PROMs, mean ODI, NRS-leg, and NRS-back improved at 1 year, but the uncontrolled design precludes efficacyinference. No adverse changes in T1-rho or T2 were observed through 1 year. In this single-center prospective pilot, intradiscal BMAC at the time of microdiscectomy was safe and feasible, with no injection-related harm through 1 year and one same-site recurrence. Without a control group and with incomplete follow-up, findings are preliminary safety data, not evidence of efficacy or reduced recurrence risk. These results support a multicenter study with longer follow-up and a controlled comparison group.

31 January 2026 in Neurospine
Verified
Journal Article
Open access
NWNoah Willett
Noah Willett
CIChibuikem Anthony Ikwuegbuenyi
Chibuikem Anthony Ikwuegbuenyi
EWEvan Wang
Evan Wang
LCLawrance K Chung
Lawrance K Chung
ARAnthony Robayo
Anthony Robayo
ADAo Spine Knowledge Forum Degenerative
Ao Spine Knowledge Forum Degenerative
To address disc reherniation, several annular repair strategies have been developed, including implantable devices, suture-based techniques, and biomaterials. This review evaluates the clinical evidence supporting these strategies. A systematic search of PubMed, Cochrane, and Embase and MEDLINE via Ovid was performed from database inception to July 2025. A combination of keywords was used in the search string. Publications were included if they were clinical studies and described closing the annulus or blocking the annulus defect with biologics, sutures, or physical devices. Exclusion criteria were animal studies, in vitro studies, non-English articles, and abstracts. A single-arm proportional meta-analysis was performed for studies reporting extractable reherniation, reoperation, or complication data. The initial search identified 1,349 records. After removal of 315 duplicates, 1,034 studies underwent screening, with 84 full texts reviewed and 62 meeting inclusion criteria. Forty-one studies (66%) assessed implantable physical devices, of which 40 (98%) evaluated the Barricaid annular closure device (ACD) (Intrinsic Therapeutics, Inc., USA). Eighteen studies (29%) evaluated suture-based closure of the annulus fibrosus, using preloaded devices, bone-anchored systems, or manual suturing techniques. Three studies (5%) examined the use of biomaterials as either an adjunct or standalone method in the form of autologous conditioned plasma, bone marrow stromal cells, and fibrin sealant. For physical devices, the pooled reherniation, reoperation, and complication rates were 4.71%, 4.84%, and 1.76% respectively. Suture-based techniques had reherniation, reoperation, and complication rates of 1.37%, 0.35%, and 0.28%, respectively. For biomaterial-based approaches, only a pooled reherniation rate was calculated (2.11%), as insufficient data were available to pool reoperation and complication rates. Annular repair following discectomy is associated with low rates of reherniation, reoperation, and complications across physical devices, suture-based techniques, and biomaterial approaches. Physical devices and suturing techniques have robust clinical evidence and show generally favorable outcomes, but results remain mixed and heterogenous across techniques. Biomaterials demonstrate early promise but are limited by small study size and short follow-up. While pooled proportional meta-analysis supports the overall safety and effectiveness of annular repair, heterogeneity and limited comparative evidence prevent determination of relative superiority.